Iterum Therapeutics ITRMF Income Statement (2017-2025)

ITRMF
$0.00 +0.00 (+0.00%)
At close: Aug 19, 2026 · 4:00 PM EDT
Income Statement Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Shares Outstanding (Entity) (Quarter)
24.01M121.55M182.59M182.78M163.37M182.90M183.36M12.23M12.60M12.81M13.03M13.04M13.50M16.47M16.58M22.71M19.70M35.69M42.13M48.99M
Revenue & cost
Revenue (Quarter)
0.39M
Gross Profit (Quarter)
0.37M
Operating items
Amortization - Intangibles (Quarter)
0.35M
Research & Development (Quarter)
2.35M2.45M2.71M1.84M3.70M3.44M3.98M4.35M5.84M6.43M8.96M14.85M9.74M3.98M2.08M3.11M1.30M0.59M1.00M1.26M
Selling, General & Administrative (Quarter)
2.29M3.40M4.27M3.03M3.13M3.93M4.07M2.68M2.09M2.10M1.86M1.83M1.69M2.19M1.90M1.78M2.12M2.78M4.18M6.49M
Other Operating Expenses (Quarter)
-18.19M0.34M-4.84M0.37M
Operating Expenses (Quarter)
4.64M5.85M6.99M4.87M6.83M7.37M8.05M7.03M7.93M8.53M10.82M16.68M11.43M6.16M3.98M4.89M-14.77M3.71M0.34M8.12M
Operating Income (Quarter)
-4.64M-5.85M-6.99M-4.87M-6.83M-7.37M-8.05M-7.03M-7.93M-8.53M-10.82M-16.68M-11.43M-6.16M-3.98M-4.89M-3.67M-3.71M-5.53M-7.73M
EBIT (Quarter)
-4.64M-5.85M-6.99M-4.87M-6.83M-7.37M-8.05M-7.03M-7.93M-8.53M-10.82M-16.68M-11.43M-6.16M-3.98M-4.89M-3.67M-3.71M-5.53M-7.73M
Non-operating items
Interest & Investment Income (Quarter)
0.26M0.18M0.17M0.18M0.15M0.13M0.12M
Other Non Operating Income (Quarter)
0.31M0.04M15.79M9.78M64.72M0.16M0.27M0.17M2.96M0.04M-0.96M13.20M-11.28M-0.02M-0.41M-0.05M1.18M-0.55M-0.02M-0.00M
Non Operating Income (Quarter)
-8.28M-93.01M-0.98M8.97M2.82M4.30M-0.77M-0.64M2.94M-0.40M-1.23M-0.30M-0.41M-0.49M-0.99M-1.07M-2.89M-1.12M-0.32M-1.12M
Net income details
EBT (Quarter)
40.80M-98.86M7.92M4.09M-3.98M-3.07M-6.39M-29.68M-4.99M-9.77M-12.06M-3.72M27.28M-7.05M-4.97M-5.96M18.35M-4.83M-6.45M-8.85M
Tax Provisions (Quarter)
-0.14M0.06M0.12M0.35M0.17M0.43M0.34M-0.57M0.10M0.12M0.19M0.16M0.14M0.05M0.03M0.14M-3.28M0.06M0.06M0.13M
Profit After Tax (Quarter)
-11.19M-98.92M7.80M3.74M-4.18M-3.50M-6.74M-29.11M-5.44M-9.89M-12.24M-3.88M-12.01M-7.10M-5.00M-6.09M-6.58M-4.89M-6.51M-8.98M
Income from Continuing Operations (Quarter)
40.94M-98.92M7.80M3.74M-4.15M-3.50M-6.74M-29.11M-5.09M-9.89M-12.24M-3.88M27.14M-7.10M-5.00M-6.09M21.63M-4.89M-6.51M-8.98M
Consolidated Net Income (Quarter)
40.94M-98.92M7.80M3.74M-4.15M-3.50M-6.74M-29.11M-5.09M-9.89M-12.24M-3.88M27.14M-7.10M-5.00M-6.09M21.63M-4.89M-6.51M-8.98M
Income towards Parent Company (Quarter)
40.94M-98.92M7.80M3.74M-4.15M-3.50M-6.74M-29.11M-5.09M-9.89M-12.24M-3.88M27.14M-7.10M-5.00M-6.09M21.63M-4.89M-6.51M-8.98M
Net Income towards Common Stockholders (Quarter)
-11.19M-98.92M7.80M3.74M-4.18M-3.50M-6.74M-29.11M-5.09M-9.89M-12.24M-3.88M-12.36M-7.10M-5.00M-6.09M-6.58M-4.89M-6.51M-8.98M
Additional items
EPS (Basic) (Quarter)
-0.47-0.810.040.02-0.03-0.02-0.04-2.38-0.42-0.78-0.95-0.30-0.95-0.46-0.30-0.30-0.33-0.14-0.16-0.20
EPS (Diluted) (Quarter)
-6.99-61.800.040.02-0.38-0.29-0.04-2.38-0.42-0.78-0.95-0.30-0.95-0.46-0.30-0.30-0.33-0.14-0.16-0.20
Shares Outstanding (Quarter)
24.01M121.55M180.02M182.73M163.37M182.90M183.36M12.23M12.24M12.68M12.94M13.04M12.96M15.43M16.55M20.04M19.70M34.06M39.94M45.80M
Shares Outstanding (Diluted) (Quarter)
1.60M1.60M204.60M202.26M10.89M12.19M183.36M12.23M12.24M12.68M12.94M13.04M12.96M15.43M16.55M20.04M19.70M34.06M39.94M45.80M
EBITDA (Quarter)
-4.64M-5.85M-6.99M-4.87M-6.83M-7.37M-8.05M-7.03M-7.93M-8.53M-10.82M-16.68M-11.43M-6.16M-3.98M-4.89M-3.67M-3.71M-5.53M-7.73M
Interest Expenses (Quarter)
0.23M9.29M0.12M7.83M0.06M6.66M6.08M5.49M4.32M3.73M3.14M2.48M0.75M0.75M0.76M2.77M0.69M12.11M11.77M
Tax Rate (Quarter)
-0.35-0.061.548.60-4.30-13.90-5.371.92-2.02-1.26-1.55-4.330.52-0.68-0.62-2.28-17.89-1.24-0.91-1.49